"The company (Lupin) has received tentative approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Brivaracetam Tablets," Lupin said
Post the clarification by the BSE on Wednesday over its new surveillance rules, dip buyers, who were sitting on the fence for a correction, lined up to buy shares of midcap and smallcap companies that had seen hefty correction over the past week.
NBCC (India): The state-owned construction company, which is in the race to acquire Jaypee Infratech Ltd (JIL), assured stuck homebuyers that its bid is concrete, fully backed by the government and the PSU will complete over 20,000 pending flats on time as per the schedule.
Reliance Power: The board of ADAG s utility company approved a preferential issue of 59.5 crore equity shares and 73 crore warrants worth Rs 1,325 crore to its promoter firm
Reliance Infrastructure. It aggregates up to Rs 1,325 crore.
Ruchi Soya: The edible oil firm, which is owned by Baba Ramdev-led Patanjali Ayurveda, has filed a draft document with SEBI to launch a follow-on public offer (FPO) for raising up to Rs 4,300 crore. The FPO is being launched to meet the SEBI norm of minimum public shareholding of 25 per cent in a listed entity.
Shares of Lupin dipped 5 per cent to Rs 1,173 on the BSE in intra-day trade on Monday after the pharmaceutical company said it has received a Warning Letter (WL) for its manufacturing plant at Somerset, New Jersey. This is the only manufacturing plant of Lupin located in the US.
However, Lupin said the company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility.
At 09:57 am, Lupin was trading 3 per cent lower at Rs 1,194, as compared to 0.37 per cent decline in the S&P BSE Sensex. A combined 1.4 million shares have changed hands on the counter on the NSE and BSE, so far.